Action 31: Work together in a coordinated and transparent manner to ensure paediatric formulations are rapidly registered, introduced, and made widely available at an affordable cost in a maximum of high-burden countries.

Action 32: Identify alternative incentives and innovative financial mechanisms for the research, development and sustained supply of paediatric formulations, including advanced purchase commitments or other interventions.

Action 33: In addition to paediatric drugs and formulations in the pipeline, support the greater use of currently available WHO prequalified diagnostics and drugs in the WHO recommended regimens.


34. Tackle the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accesing testing and treatment.

35. Promote provider initiated testing and counseling (PITC) of children outside PMTCT settings, testing of children of index HIV cases and siblings of HIV infected children, and pursue innovative avenues to identifying children living with HIV of all ages and ensuring access to testing and treatment.

36. Promote and support virological (rather than serological) testing at the 9 months of age time point for all HIV-exposed infants per WHO 2018 EID algorithm changes.

37. Support rational integration and scale up of point of care virologic platforms within laboratory networks for timely identification and monitoring of infants and children with HIV.

38. Increase literacy about viral load and promote a client-centered approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment.

39. Advocate for the elimination of user fees from diagnostic and health services in both the public and private sector.

Development of connectivity solutions that can easily offer interoperability with national laboratory health information and quality systems.

Development of, in collaboration with governments and other stakeholders, sustainable waste management solutions that are incorporated into existing national biosafety systems for the appropriate disposal of toxic laboratory products. Ensure that new products in the pipeline are environmentally friendly.

Explore the development of a device-free POC EID.

Consideration of the Inclusion of HIV-2 for EID and viral load for conventional and POC testing in new technology development.


57. Advocate for and support Ministries of Health to quickly adopt and implement WHO Pediatric HIV Testing and Treatment Guidelines

58. Advocate for and support Ministries of Health to rapidly transition to optimal paediatric formulations as outlined by the WHO guidelines, provide coordinated support for the development and implementation of transition plans, inform clinicians and patients of the value of transitioning to new formulations, and ensure communication of reliable information on the availability of new formulations in-country.

59. Tackle the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment.

60. Promote awareness of, political and financial support for, and full implementation of the Action Plan among all relevant stakeholders.

60. UNAIDS has launched both the 2019 Global report and the 2019 Start Free Stay Free Aids Free report highlighting the main results on PMTCT and paediatrics that show the failure to reach the 2018 targets. On 12 December 2019, the UNAIDS Programme Coordinating Board (PCB) thematic segment will focus on children and youth and give the opportunity to discuss strategies to increase uptake of services to children and youth.